证券代码：002788 证券简称：鹭燕医药 编号：2017-006 鹭燕医药股份有限公司 投资者关系活动记录表 | --- | --- | --- | |--------------|---------------------------------|--------------------------------------------------| | | √ | 特定对象调研 □分析师会议 | | 投资者关系 | □ 媒体采访 □业绩说明会 | | | 活动类别 | □新闻发布会 □路演活动 | | | | □ 现场参观 | □其他（请文字说明其他活动内容） | | | 天风证券：柴博 | | | 参与单位名称 | 中科林德：李仁钧 | | | 及人员姓名 | 中银国际：张威亚 泰康资产：涂健 | | | | 华泰柏瑞基金：盛夏 | | | 时间 | 2017 年 12 月 7 | 日下午 14:00-16:00 | | 地点 | 鹭燕医药会议室 | | | 上市公司 | | 副总经理兼董事会秘书雷鸣、证券事务代表阮翠婷 | | 接待人员姓名 | | | | 投资者关系活 | 1 | 、省外的分销业务拓 ...

证券代码：002788 证券简称：鹭燕医药 编号：2017-005 鹭燕医药股份有限公司 投资者关系活动记录表 | --- | --- | --- | |--------------|---------------------------------|---------------------------------| | | √ | 特定对象调研 □分析师会议 | | 投资者关系 | □ 媒体采访 □业绩说明会 | | | 活动类别 | □新闻发布会 □路演活动 | | | | □ 现场参观 | □其他（请文字说明其他活动内容） | | | 平安证券：叶寅 | | | | 君重资本：禚晓龙 | | | 参与单位名称 | 红土创新：凌军 | | | | | | | 及人员姓名 | 浙商证券：李晓明 | | | | 沣杨资产：吴亮 国联安基金：焦阳 | | | 时间 | 2017 年 11 月 17 | 日上午 10:00-11:30 | | 地点 | 鹭燕医药会议室 | | | 上市公司 | 证券事务代表阮翠婷 | | | 接待人员姓名 | | | | 投资者关系活 | 1 | 、省外的分销业务拓展规划如何？ ...

证券代码：002788 证券简称：鹭燕医药 编号：2019-003 鹭燕医药股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-----------------------|-------------------------|---------------------------------------------------------| | | √ | 特定对象调研 □分析师会议 | | 投资者关系 | □ | 媒体采访 □业绩说明会 | | 活动类别 | □新闻发布会 □路演活动 | | | | □ 现场参观 | □其他（请文字说明其他活动内容） | | 参与单位名称 | | 长城国瑞证券：黄文忠、胡晨曦 | | 及人员姓名 | | | | 时间 | 2019 年 8 月 23 | 日上午 9:30-10:30 | | 地点 | 鹭燕医药会议室 | | | 上市公司 接待人员姓名 | | 副总经理兼董事会秘书雷鸣、叶泉青 | | 投资者关系活 | 1 | 、驱动公司业绩增长的主要因素是什么？ | | 动主要内容介 | 公司 2018 | 年度营业总收入为 115.05 亿元， ...

编号：2018-002 证券代码：002788 证券简称：鹭燕医药 鹭燕医药股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-----------------------|-------------------------|----------------------------------------------------------------| | | √ | 特定对象调研 □分析师会议 | | 投资者关系 | □ | 媒体采访 □业绩说明会 | | 活动类别 | □新闻发布会 □路演活动 | | | | □ 现场参观 | □其他（请文字说明其他活动内容） | | 参与单位名称 | 华创证券：吴璋怡 | | | 及人员姓名 | 磐伫咨询：马超群 | | | 时间 | 2018 年 11 月 8 | 日上午 10:00-11:00 | | 地点 | 鹭燕医药会议室 | | | 上市公司 接待人员姓名 | | 副总经理兼董事会秘书雷鸣、证券事务代表阮翠婷 | | 投资者关系活 | | 1、省外的分销业务拓展情况如何？ | | 动主要内容介 绍 | 公司 2017 | 年已开始 ...

证券代码：002788 证券简称：鹭燕医药 编号：2019-002 鹭燕医药股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-----------------|-----------------------------------|---------------------------------------------------| | | √ | 特定对象调研 □分析师会议 | | 投资者关系 | □ 媒体采访 □业绩说明会 | | | 活动类别 | □新闻发布会 □路演活动 | | | | □ 现场参观 | □其他（请文字说明其他活动内容） | | 参与单位名称 | 兴业证券：杜向阳、周奕吉 | | | 及人员姓名 | 华大共赢：纪昌涛 交银施罗德：刘牧 | | | 时间 | 2019 年 3 月 1 | 日下午 15:00-16:30 | | 地点 | 鹭燕医药会议室 | | | 上市公司 | | 副总经理兼董事会秘书雷鸣、证券事务代表阮翠婷 | | 接待人员姓名 | | | | 投资者关系活 | 1 | 、驱动公司业绩增长的主要因素是什么？ | | 动主要内容介 绍 | ...

编号：2019-001 证券代码：002788 证券简称：鹭燕医药 鹭燕医药股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-----------------------|--------------------------|----------------------------------------------------------------| | | √ | 特定对象调研 □分析师会议 | | 投资者关系 | □ | 媒体采访 □业绩说明会 | | 活动类别 | □新闻发布会 □路演活动 | | | | □ 现场参观 | □其他（请文字说明其他活动内容） | | 参与单位名称 | 厦航投资：林健津、况小平 | | | 及人员姓名 | 厦航资管：涂峰 | | | 时间 | 2019 年 2 月 14 | 日上午 10:00-12:00 | | 地点 | 鹭燕医药会议室 | | | 上市公司 接待人员姓名 | | 副总经理兼董事会秘书雷鸣、证券事务代表阮翠婷 | | 投资者关系活 | 1 | 、省外的分销业务拓展情况如何？ | | 动主要内容介 | 公司 2017 | 年 ...

证券代码：002788 证券简称：鹭燕医药 编号：2021-001 鹭燕医药股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-------------------------|------------------------------------------|--------------------------------------------------------------------------| | | □特定对象调研 □分析师会议 | | | 投资者关系 | □媒体采访 √业绩说明会 | | | 活动类别 | □新闻发布会 | □路演活动 | | | □现场参观 | | | | □其他（请文字说明其他活动内容） | | | 参与单位名称 及人员姓名 | 线上参与 2020 | 年度网上业绩说明会的投资者 | | | | | | 时间 | 2021 年 5 月 10 日 | 15:00-17:00 | | 地点 | 通过"鹭燕医药投资者关系" | 小程序网络远程方式举行 | | 上市公司 | | 董事长兼总经理吴金祥先生、独立董事林志扬先生、董事会办公室主任 | | ...

证券代码：002788 证券简称：鹭燕医药 编号：2021-002 鹭燕医药股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-------------------------|------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | √特定对象调研 □分析师会议 | | | 投资者关系 | □媒体采访 □业绩说明会 | | | 活动类别 | □新闻发布会 | □路演活动 | | | □现场参观 | □其他（请文字说明其他活动内容） | | 参与单位名称 及人员姓名 | 兴业证券：黄昭宇 | | | 时间 | 2021 年 7 月 29 日 | 10:30-12:00 | | | | | | 地点 | 鹭燕医药会议室 | | ...

Financial Performance - The company's operating revenue for Q3 2022 was CNY 4,982,869,676.98, representing a 10.04% increase compared to the same period last year[6] - The net profit attributable to shareholders for Q3 2022 was CNY 82,094,778.88, an increase of 3.61% year-on-year[6] - The company reported a basic earnings per share of CNY 0.21 for Q3 2022, up 5.00% from the same period last year[6] - The net profit for the third quarter of 2022 was CNY 251,958,323, an increase of 9.8% compared to CNY 229,058,402 in the same period last year[25] - The total comprehensive income for the quarter was CNY 255,741,712.26, compared to CNY 228,724,810.17 in the prior year, indicating a growth of 11.8%[25] - The company's total profit for the quarter was CNY 332,785,948.04, compared to CNY 305,016,168.31 in the previous year, marking an increase of 9.1%[25] Cash Flow and Assets - The net cash flow from operating activities increased by 123.80% year-on-year, indicating improved operational efficiency and effective cash management[10] - The net cash flow from operating activities was CNY 92,154,381.20, a significant improvement from a negative cash flow of CNY -387,139,805.67 in the previous year[26] - Cash and cash equivalents at the end of the period were CNY 286,140,227.71, down from CNY 374,128,456.22 at the end of the previous year[27] - The company incurred a net cash outflow from investing activities of CNY -208,475,358.79, slightly improved from CNY -214,096,083.22 in the previous year[27] - The net cash flow from financing activities was CNY 94,556,945.34, a decrease from CNY 500,284,035.29 in the same period last year[27] - The total assets at the end of the reporting period were CNY 10,754,928,476.53, reflecting a 7.63% increase from the previous year[6] Shareholder Information - The total number of common stock shareholders at the end of the reporting period is 28,361[12] - Xiamen Maidi Technology Co., Ltd. holds 35.53% of shares, totaling 138,030,674 shares, with 35,907,834 shares pledged[12] - The top 10 shareholders include Xiamen Mingyuan Hongqiao High-tech Venture Capital Partnership with 1.51% (5,881,192 shares) and individual shareholder Li Weiyang with 1.27% (4,936,545 shares)[12] - The total number of shareholders with voting rights restored for preferred shares is 0[13] - The company has reported no participation in margin financing activities among the top 10 shareholders[12] Legal Matters - The company has ongoing legal matters related to its subsidiary Chengdu Hechuang Pharmaceutical Group, involving a total claim of 23.1 million RMB for breach of contract[17] - Chengdu Hechuang has received bankruptcy distribution payments totaling 78.005 million RMB and 55.3911 million RMB from the bankruptcy administrator of Guizhou Dechangxiang Pharmaceutical Co., Ltd.[15] - The company is actively pursuing legal actions to recover losses from Guizhou Mingrun Construction Engineering Co., Ltd., with a claim of 39.6973 million RMB plus interest[18] - The company has a total of 6,000,000 RMB in bank deposits seized as part of the enforcement of a court ruling related to the bankruptcy case[15] - The company is coordinating with multiple parties to resolve execution-related matters and ensure that collateral is prioritized for debt repayment[16] Investments and Growth - The company’s long-term borrowings increased by 49.06% to CNY 333,119,800.00, primarily due to new project loans[9] - The company’s investment properties increased by 406.86% to CNY 24,936,400.00, attributed to acquisitions through judicial auctions[9] - The company has made significant investments in ongoing projects, including modern Chinese medicine production and new pharmaceutical facilities[9] Operating Costs - Total operating costs amounted to ¥13,967,712,770.29, up 10.15% from ¥12,679,853,348.75 year-on-year[24] - Operating profit for the period was ¥331,260,720.17, a slight increase from ¥305,319,751.77 in the previous year[24]

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 9,340,896,235.85, representing a 10.22% increase compared to CNY 8,474,180,571.65 in the same period last year[20]. - The net profit attributable to shareholders of the listed company was CNY 168,764,960.24, up 10.34% from CNY 153,140,313.21 in the previous year[20]. - Basic and diluted earnings per share both increased to CNY 0.43, reflecting a growth of 10.26% compared to CNY 0.39 in the previous year[20]. - The company reported a net profit margin of 16% for the first half of 2022, compared to 15% in the first half of 2021, indicating a slight improvement in profitability[108]. - The company reported a net profit margin of 22% for the first half of 2022, indicating strong operational efficiency[109]. - The company reported a net profit of 865.15 million for the first half of 2022, down from 1,000 million in the first half of 2021, indicating a decrease of about 13.5%[111]. - The company reported a total comprehensive income of CNY 171,030,225.87, compared to CNY 149,093,839.88 in the previous year, an increase of 14.7%[160]. - The total comprehensive income for the first half of 2022 was 245.1 million yuan, compared to 167.2 million yuan in the same period of the previous year, representing an increase of approximately 46.6%[179]. Cash Flow and Assets - The net cash flow from operating activities improved significantly, reaching CNY 18,435,029.72, a 106.00% increase from a negative CNY 296,848,523.55 in the same period last year[20]. - The company's cash flow from operating activities improved significantly, generating ¥18,435,029.72 compared to a negative cash flow of -¥307,051,752.30 in the previous year, marking a 106.00% increase[52]. - The company's cash and cash equivalents increased by 134.04% to ¥60,851,641.22 from a negative balance of -¥178,750,661.72 in the previous year[52]. - The total assets at the end of the reporting period were CNY 10,598,189,169.63, a 6.06% increase from CNY 9,992,695,467.80 at the end of the previous year[20]. - The total assets at the end of the reporting period were 5.2 billion yuan, with total liabilities of 2.4 billion yuan[171]. - The total assets at the end of the first half of 2022 were 1,230 million yuan, up from 1,159 million yuan at the end of the previous year, indicating a growth of approximately 6.1%[180]. Market Position and Strategy - The company ranked 15th among the top 100 pharmaceutical wholesale enterprises in China in 2021, maintaining its position as the largest pharmaceutical distribution company in Fujian Province for thirteen consecutive years[28]. - The company is expanding its market presence through acquisitions in Sichuan, Jiangxi, and Hainan provinces, enhancing its competitive edge in these regions[31]. - The company aims for the top 100 pharmaceutical wholesale enterprises to account for 98% of the market by 2025, indicating a trend towards increased market concentration[29]. - The company is actively investing in traditional Chinese medicine, with ongoing projects to expand production capacity and national distribution of Chinese herbal pieces[32]. - The company is transitioning from a distributor to a comprehensive service provider by enhancing its capabilities in pharmaceutical services, market access, and terminal marketing[34]. - The company is exploring market expansion strategies, with plans to increase its presence in three new regions by the end of 2022[109]. - The company is exploring potential mergers and acquisitions to bolster its market position and enhance product offerings[110]. Operational Efficiency and Cost Management - The gross margin for the first half of 2022 was reported at 24%, slightly up from 23% in the previous year, indicating improved cost management[108]. - The gross margin for the first half of 2022 improved to 24%, reflecting better cost management and pricing strategies[114]. - The company aims to reduce operational costs by 5% through improved supply chain management initiatives[113]. - The company has set a target to reduce operational costs by 5% over the next year through process optimization[114]. - The company has implemented a centralized procurement mechanism for bulk goods, enhancing bargaining power with suppliers and reducing procurement costs[46]. Research and Development - Research and development expenses increased to 288.83 million in the first half of 2022, up from 250 million in the same period of 2021, highlighting a focus on innovation[108]. - The R&D budget for 2022 has been increased to 950 million, representing a 20% increase from the previous year, to support new technology initiatives[109]. - The company has allocated 270 million yuan for research and development in the current fiscal year[173]. - The company has allocated 1.1 million CNY for new technology development in the upcoming fiscal year[176]. - The company has initiated a new strategy focusing on enhancing its research and development capabilities to innovate and improve product offerings[179]. Social Responsibility and Community Engagement - The company is committed to social responsibility, actively participating in the fight against COVID-19 by supplying necessary medical materials[33]. - The company supplied nearly 7 million bags of traditional Chinese medicine during the COVID-19 outbreak in Fujian Province, covering nearly 1 million people in quarantine areas and frontline medical workers[85]. - The company delivered 30.53 million COVID-19 test kits in the first half of 2022, fulfilling its social responsibility in combating the pandemic in Fujian Province[85]. - The company actively participated in the centralized procurement and distribution of COVID-19 related testing reagents organized by health authorities in Fujian Province[85]. Risks and Challenges - The company faces intensified market competition, particularly in the pharmaceutical distribution sector, which may impact its market share[70]. - The ongoing price reduction policies in the healthcare sector could compress the company's profit margins if sales volumes do not increase accordingly[71]. - The company faces goodwill impairment risks if acquired companies do not meet performance expectations, which could significantly impact overall performance[76]. - The company's operating cash flow is lower than net profit due to long collection cycles from medical institutions and short credit periods from suppliers, leading to potential liquidity pressures[76]. Governance and Compliance - The financial report was approved by the board of directors on August 19, 2022, indicating a structured governance process[188]. - The company prepares financial statements based on the going concern assumption and adheres to the accounting standards and guidelines set forth by the relevant authorities[190]. - The company's financial statements comply with the requirements of the accounting standards, accurately reflecting its financial position and operating results[193].